A call for greater consideration for the role of vaccines in national strategies to combat antibiotic-resistant bacteria: Recommendations from the National Vaccine Advisory Committee

Public Health Reports

Volumn 131, Issue 1, 2016, Pages 11-16

  Orenstein, Walter A ^a   Gellin, Bruce G ^b   Beigi, Richard H ^c   Despres, Sarah ^d   Lynfield, Ruth ^e   Maldonado, Yvonne ^f   Mouton, Charles ^g   Rawlins, Wayne ^h   Rothholz, Mitchel C ⁱ   Smith, Nathaniel ^j   Thompson, Kimberly ^k   Torres, Catherine ^l   Viswanath, Kasisomayajula ^m   Gordon, Jennifer ^b   Billington, John ^b   Seib, Katy ^b   Daum, Robert ^b  

^a EMORY UNIVERSITY   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d PEW CHARITABLE TRUSTS   (United States)

^e MINNESOTA DEPARTMENT OF HEALTH   (United States)

^f STANFORD UNIVERSITY   (United States)

^g MEHARRY MEDICAL COLLEGE   (United States)

^h AETNA   (United States)

ⁱ AMERICAN PHARMACISTS ASSOCIATION   (United States)

^j ARKANSAS DEPARTMENT OF HEALTH   (United States)

^k UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^l Southern New Mexico Human Development   (United States)

^m HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; VACCINE; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; HAEMOPHILUS VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADVISORY COMMITTEE; ANTIBIOTIC RESISTANCE; DRUG RESEARCH; ECONOMIC ASPECT; HEALTH PROGRAM; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NOTE; PEPTOCLOSTRIDIUM DIFFICILE; PRACTICE GUIDELINE; PRIORITY JOURNAL; BACTERIAL INFECTIONS; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EPIDEMIOLOGY; HUMAN; STAPHYLOCOCCAL INFECTIONS; UNITED STATES;

ADVISORY COMMITTEES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HAEMOPHILUS VACCINES; HUMANS; INFLUENZA VACCINES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMOCOCCAL VACCINES; STAPHYLOCOCCAL INFECTIONS; UNITED STATES;

EID: 84953321336     PISSN: 00333549     EISSN: 14682877     Source Type: Journal    
DOI: 10.1177/003335491613100105     Document Type: Note

References (44)

1. Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014 [cited 2015 Mar 14]. Available from: http://www.jpiamr.eu/wp-content/uploads/2014/12/AMR-review-paper-tackling-a-crisis-for-the-health-and-wealth-of-nations_1-2.pdf
2. Centers for Disease Control and Prevention (US). Antibiotic resistance threats in the United States, 2013. 2014 [cited 2015 Mar 14]. Available from: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
3. Keown OP, Warburton W, Davies SC, Darzi A. Antimicrobial resistance: addressing the global threat through greater awareness and transformative action. Health Aff 2014;33:1620-6
4. The White House (US). National strategy for combating antibioticresistant bacteria. 2014 [cited 2015 Mar 16]. Available from: https://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf
5. President’s Council of Advisors on Science and Technology. Repor to the president on combating antibiotic resistance. 2014 [cited 2015 Mar 16]. Available from: https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf
6. The White House (US). Executive order—combating antibioticresistant bacteria. 2014 [cited 2015 Mar 16]. Available from: https://www.whitehouse.gov/the-press-office/2014/09/18/executive-order-combating-antibiotic-resistant-bacteria
7. The White House (US). National action plan for combating antibiotic-resistant bacteria. 2015 [cited 2015 Mar 27]. Available from: https://www.whitehouse.gov/sites/default/files/docs/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf
8. The White House (US), Office of the Press Secretary. Fact sheet: president’s 2016 budget proposes historic investment to combat antibiotic-resistant bacteria to protect public health. 2015 Jan 27 [cited 2015 Mar 16]. Available from: https://www.whitehouse.gov/the-press-office/2015/01/27/fact-sheet-president-s-2016-budget-proposes-historic-investment-combat-a
9. Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 2007;298:2155-63
10. Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1993;42(RR-13): 1-15
11. Mason EO, Kaplan SL, Lamberth LB, Hinds DB, Kvernland SJ, Loiselle EM, et al. Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience. J Clin Microbiol 1982;15:543-6
12. Adams DA, Jajosky RA, Ajani U, Kriseman J, Sharp P, Onwen DH, et al. Summary of notifiable diseases—United States, 2012. MMWR Morb Mortal Wkly Rep 2014;61(53):1-121
13. Department of Health and Human Services (US). Healthy People 2020—immunization and infectious diseases. 2015 [cited 2015 Mar 23]. Available from: https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives
14. Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg Infect Dis 1996;2:176-82
15. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000;343:1917-24
16. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63
17. Wilby KJ, Werry D. A review of the effect of immunization programs on antimicrobial utilization. Vaccine 2012;30:6509-14
18. Cohen R. The need for prudent use of antibiotics and routine use of vaccines. Clin Microbiol Infect 2009;15(Suppl 3):21-3
19. Lee GC, Reveles KR, Attridge RT, Lawson KA, Mansi IA, Lewis JS 2nd, et al. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med 2014;12:96
20. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis 2003;22:10-6
21. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to nonpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis 2007;196:1346-54
22. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 2015;15:301-9
23. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged $65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63(37):822-5.
24. Grijalva C, Wunderink R, Williams D, Al E. Distribution of pneumococccal serotypes detected through urine analysis among US adults hospitalized with pneumonia after introduction of PCV13. In: International Symposium on Pneumococci and Pneumococcal Diseases 2014; 2014 Mar 9–13; Hyderabad, India
25. Misurski DA, Lipson DA, Changolkar AK. Inappropriate antibiotic prescribing in managed care subjects with influenza. Am J Manag Care 2011;17:601-8
26. Kash JC, Taubenberger JK. Infectious disease theme issue: the role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol 2015;185:1528-36
27. Centers for Disease Control and Prevention. Flu vaccination coverage, United States, 2013–14 influenza season. 2014 [cited 2015 Mar 27]. Available from: http://www.cdc.gov/flu/fluvaxview/coverage-1314estimates.htm
28. Kwong JC, Maaten S, Upshur REG, Patrick DM, Marra F. The effect of universal influenza immunization on antibiotic prescriptions: an ecological study. Clin Infect Dis 2009;49:750-6
29. Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, et al. Health care-associated invasive MRSA infections, 2005–2008. JAMA 2010;304:641-8
30. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 2013;173:1970-8
31. Centers for Disease Control and Prevention (US). Active Bacterial Core surveillance report, Emerging Infections Program Network, methicillin-resistant Staphylococcus aureus, 2012. 2012 [cited 2015 Mar 29]. Available from: http://www.cdc.gov/abcs/reports-findings/survreports/mrsa12.pdf
32. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012;54:560-7
33. Kaslow DC, Shiver JW. Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development. Annu Rev Med 2011;62:201-15
34. Lessa FC, Gould C V, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55(Suppl 2):S65-70
35. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009;7:526-36
36. Chitnis AS, Holzbauer SM, Belflower RM, Winston LG, Bamberg WM, Lyons C, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013;173:1359-67
37. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-34
38. Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 2012;28:1-9
39. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010;51:1306-13
40. Lee BY, Popovich MJ, Tian Y, Bailey RR, Ufberg PJ, Wiringa AE, et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010;28:5245-53
41. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect 2012;18:282-9
42. O’Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007;28:1219-27
43. Department of Health and Human Services (US), Office of the Assistant Secretary for Planning and Evaluation. Analytical framework for examining the value of antibacterial products. 2014 [cited 2015 May 30]. Available from: http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm
44. Sahoo A. Vaccines 2011: market analysis, key players and critical trends in a fast-changing industry. Rockville (MD): Kalorama Information; 2011